secwatch.observer — SEC 8-K summary
======================================

Issuer:     MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)
CIK:        0001823239
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0001823239-23-000079
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Maravai Q2 revenue $68.9M, down 72%; net loss $11.9M; CEO transition to Trey Martin
--------------------------------------------------------------------------------

- Revenue $68.9M, down 71.6% YoY; net loss $(11.9)M vs net income $156.7M prior year.
- Nucleic Acid Production revenue $53.3M (-76.4%), including $11.6M CleanCap; Biologics Safety Testing $15.6M (-10.5%).
- Appointed Trey Martin as CEO effective July 27, 2023; Carl Hull remains Executive Chair.
- Took occupancy of new 32,000-sq-ft cGMP mRNA facility in San Diego; expanded enzyme R&D in Florida.
- Updated 2023 financial guidance conservatively; no specific numbers provided in filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1823239/000182323923000079/0001823239-23-000079-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1823239/000182323923000079/mrvi-20230807.htm
  HTML page:      https://secwatch.observer/filing/0001823239-23-000079

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer